Atlas Trials

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Clinical trial NCT02332980 · COMPLETED

Trial details

NCT number
NCT02332980
Sponsor
Mayo Clinic
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Marginal Zone LymphomaRecurrent Nodal Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Splenic Marginal Zone LymphomaRecurrent Waldenstrom Macroglobulinemia
Start date
2015-02-19
Primary completion
2021-08-10
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.